To NASDAQ OMX Copenhagen A/S

Investor News No. 08-13 / Copenhagen, August 30, 2013

Topotarget will be presenting at the 15th Annual Rodman & Renshaw Global Investment Conference which is being held in New York on September 8-10, 2013.

Anders Vadsholt, CEO of Topotarget A/S, will be presenting at the Rodman and Renshaw conference on September 10, 2013 at 4.30 pm EDT at the Millennium Broadway Hotel in New York City, USA.

Topotarget A/S
For further information, please contact:
Anders Vadsholt, CEO: Direct: +45 39178345

Background information

About Topotarget

Topotarget (NASDAQ OMX: TOPO) is a Scandinavian-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of  hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.

Topotarget Safe Harbor Statement

This announcement may contain forward-looking statements, including statements about Topotarget A/S' expectations to the progression of Topotarget A/S' clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.

distributed by